New blood pressure drug HJB647 enters first human tests

NCT ID NCT07644364

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called HJB647 in Japanese adults with elevated blood pressure or mild-to-moderate hypertension. The main goal is to check safety and how the drug moves through the body. About 74 participants will receive either HJB647 or a placebo, with doses given once or multiple times.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HJB647 (oral capsule)

What this could lead to

If successful, this could lead to a new treatment option for high blood pressure.

What could go wrong

This is an early Phase 1 trial with only 74 participants, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact